DR. LANCE ALLEN LIOTTA, M.D., PH.D.
Medical Laboratory at Bradley Blvd, Bethesda, MD

2011020, Aug 18, 2011

Aug 5, 2009

13/057409

Lance A. Liotta - Bethesda MD, US
Mariaelena Pierobon - Manassas VA, US
Alessandra Sllvestri - Capriva Del Friuu, IT

George Mason Intellectual Properties, Inc. - Fairfax VA

A61K 39/395, C12Q 1/48, C12Q 1/37, C40B 30/04, C12Q 1/02, G01N 33/53, G01N 33/573, A61K 31/415, A61K 31/365, A61K 31/439, A61K 31/517, A61K 31/5377, A61K 31/506, A61K 31/404, A61K 31/4164, A61P 35/00, A61P 35/04, G06F 19/00

4241331, 435 15, 435 23, 506 9, 435 29, 435 71, 435 74, 514406, 514473, 514291, 5142664, 51426624, 5142345, 51425218, 51425219, 514414, 514400, 702 19

The present invention relates to the identification and diagnostic use of biomarkers in primary colorectal cancer tumors whose activation level are predictive of the likelihood of the onset of metastatic disease. These biomarkers may be used to determine the suitability of a patient for aggressive and/or targeted treatments. Kits and compositions of the invention are also provided.

2014003, Jan 30, 2014

Mar 27, 2013

13/851644

Lance A. Liotta - Bethesda MD, US
Mariaelena Pierobon - Manassas VA, US
Alessandra Silvestri - Capriva del Friuli, IT

G01N 33/574

4241331, 506 9, 435 723, 435 74, 506 18, 514406, 514473, 514291, 5142664, 51426624, 5142345, 4241381, 514386, 702 19

The present invention relates to the identification and diagnostic use of biomarkers in primary colorectal cancer tumors whose activation level are predictive of the likelihood of the onset of metastatic disease. These biomarkers may be used to determine the suitability of a patient for aggressive and/or targeted treatments. Kits and compositions of the invention are also provided.

2010014, Jun 10, 2010

Oct 31, 2007

12/446937

Emanuel Petricoin - Gainesville VA, US
Weidong Zhou - Manassas VA, US
Serena Camerini - Napoli, IT
Maria Letizia Polci - Chieti, IT
Lance Liotta - Bethesda MD, US

G01N 33/53, G01N 33/00, C12Q 1/37, C07K 16/18

435 725, 436 86, 435 792, 435 23, 5303871, 5303881, 5303891, 5303873

Low molecular weight (LMW) peptides have been discovered that are indicative of colorectal cancer. Evaluating patient samples for the presence of such LMW peptides is an effective means of detecting colorectal cancer and monitoring the progression of the disease. The LMW peptides are particularly useful in detecting colorectal cancer during its early stages.

6793172, Sep 21, 2004

Jun 30, 2003

10/296137

Lance A. Liotta - Bethesda MD 20817

B64C 300

244 124, 244 4 R, 244 45 R, 446 34

An aircraft which is designed for remote controlled slow flight, indoor or in a small outdoor yard or field. The aerial lifting body is defined by a series of lightweight planar or thin airfoil surfaces (A , A , A , A ) arranged in a radially symmetrical configuration. Suspended within the cavity (O) formed by the thin airfoil surfaces (A , A , A , A ) is a thrust generating propeller system (C) that is angled upwardly and that can be regulated remotely so as to change the angle of the thrust vector within the cavity (O) for steering. Lifting, stability, turning, and general control of the direction of motion in flight is accomplished without any formal wings, rudder, tail, or control surfaces.

2004005, Mar 18, 2004

Jul 10, 2003

10/333374

Michael Emmert-Buck - Silver Spring MD, US
Chad Haldeman-Englert - Mesa AZ, US
Robert Bonner - Washington DC, US
Lance Liotta - Bethesda MD, US

G01N033/53

435/007100

The present disclosure concerns methods, systems, and devices for analyzing a biological material, such as a cellular or other specimen. In one disclosed example, the method selectively transfers biomolecules from a target region of interest in a biological sample (such as a tissue section). The transfer may occur, for example, by selectively focally altering a characteristic of a transfer layer adjacent the target region, such that the biomolecules can move through the altered area of the transfer layer. In particular examples, the transfer layer is altered by focally increasing a permeability of the transfer layer, for example by removing a focal portion of the transfer layer, and transporting the biomolecules through the altered region of the transfer layer, to microdissect the biomolecules of interest from the biological sample. In yet other embodiments, the microdissected biomolecules can be applied to an analysis substrate containing an identification molecule, such as a nucleic acid array, layered expression scan, or wells containing antibodies. Transfer microdissection allows biomolecules from regions of interest in the biological specimen to be selectively analyzed. For example, nests of highly a typical or metastatic cells in a tumor section can be analyzed for differential expression of certain proteins.

4677058, Jun 30, 1987

May 19, 1983

6/496230

Karl Tryggvason - 90230 Oulu 23, FI
Lance A. Liotta - Bethesda MD

G01N 33577

435 7

Basement membrane collagen degrading enzymes are provided which are useful for the detection of malignant cells with metastatic activity. Means for detecting such cells are also provided.

2012010, May 3, 2012

Jun 21, 2010

13/379345

Lance Liotta - Bethesda MD, US
Virginia Espina - Rockville MD, US
Alessandra Luchini - Burke VA, US
Davide Tamburro - Bristow VA, US

G01N 21/75

436501

This invention describes the identification of novel organic dye chemistries that can be used as affinity baits to capture proteins and other biomolecules useful in the fields of medical diagnostics, environmental science, toxicology, and infectious disease. Incorporation of unique affinity dye compounds within hydrogel capture particles improves analyte yield and preanalytical precision, and stabilizes the analyte against degradation, while increasing measurement sensitivity. The particles in this invention can be used for routine clinical testing as well as for discovery of low abundance disease biomarkers. Example hydrogel particles containing new high affinity bait chemistries were used to identify a new set of human serum biomarkers.

2012008, Apr 5, 2012

Jun 2, 2011

13/152204

Claudius Mueller - Gainesville VA, US
Lance Liotta - Bethesda MD, US
Emanuel Petricoin - Gainesville VA, US
Virginia Espina - Rockville MD, US

C12Q 1/02, C40B 30/04, C40B 30/06

506 9, 435 29, 506 10

Glioblastoma multiforme biomarkers, methods, and compositions are provided. Methods of selecting a treatment for a patient with a brain neoplasm, including Glioblastoma multiforme, are provided. Methods of treating a patient at risk for Glioblastoma multiforme are provided.

2011013, Jun 9, 2011

Dec 2, 2010

12/959096

Domenico NAPOLETANI - Fairfax VA, US
Michele Signore - Rome, IT
Timothy Sauer - Fairfax VA, US
Lance Liotta - Bethesda MD, US
Emanuel Petricoin - Gainesville VA, US

G06G 7/48, G06F 17/10

703 2, 703 11

A system and method for creating at least one new network, comprising: selecting at least one node and at least one set of reactions where reagents in each reaction of the at least one set of reactions are known in at least one reference network; and creating at least one new network by causing the at least one new network to behave in a similar way with respect to the at least one node and the at least one set of reactions as the at least one reference network reacts with the at least one node and the at least one set of reactions.

2008024, Oct 2, 2008

Mar 27, 2008

12/057163

Emanuel F. Petricoin - Gainesville VA, US
Lance A. Liotta - Bethesda MD, US

Theranostics LLC - Rockville MD

G01N 33/569, C12Q 1/02, G06F 19/00

702 19, 435 29, 435 721

A theranostics technique for describing signaling pathway activity within a cellular or tissue sample may include analyzing a cellular sample to obtain sample quantitative values for a series of target protein modification levels reflected in a set of a plurality of protein biomarkers in the sample. The sample quantitative values may be compared to reference quantitative values for the same series of protein modification levels. The reference quantitative values may be statistically processed from a plurality of comparable samples. The sample quantitative values may be displayed in relation to the reference quantitative values in a way that may suggest a specific course of treatment.